Status:
UNKNOWN
Light-Emitting Diode (LED) Light for Seasonal Affective Disorder (SAD) Treatment
Lead Sponsor:
Brigham and Women's Hospital
Conditions:
Seasonal Affective Disorder
Eligibility:
All Genders
18-64 years
Phase:
NA
Brief Summary
Recurrent fall/winter major depression (known as Seasonal Affective Disorder (SAD)) is a prevalent and disruptive disorder whose pathophysiological basis is unknown, but several hypotheses attribute a...
Detailed Description
BACKGROUND AND SIGNIFICANCE Discovery in the late 1970s that bright light affects neuroendocrine rhythms such as melatonin secretion, and can reset the circadian pacemaker in humans, paved the way fo...
Eligibility Criteria
Inclusion
- History of recurrent major depressive episodes with winter-type seasonal pattern by Diagnostic and Statistical Manual of the American Psychiatric Association, 4th Ed. (DSM-IV) criteria (American Psychiatric Association, 1990), based on diagnostic interview utilizing the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID) and graphic diagnostic tool
- Free of medical illness, not pregnant, as determined by detailed history and physical examination including blood and urine chemistries and thyroid function tests
Exclusion
- History of concurrent psychiatric illness that would preclude compliance with the protocol and ability to complete the study safely
- Active suicidal or homicidal ideation or plan
- Variable psychiatric symptoms such as rapid cycling or severe premenstrual syndrome that could interfere with accurate assessment of the treatment effect
- History of substance abuse/dependence with less than one year remission
- GAF \< 50
- Light treatment in the previous month
- Pregnant or lactating
- Antidepressant medications in the previous month
- Nightwork or other habitual alteration of sleep/wake cycle
- Medical conditions that affect mood or produce hallmark symptoms of mood disorder
- Use of photosensitizing medications (amiodarone, benoxaprofen, chlorpromazine, demeclocycline, fleroxacin, nalidixic acid, ofloxacin, piroxicam, porfimer, psoralens, quinidine, temoporfin) or remedies (St. John's wort)
- Macular degeneration or cataract
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00114322
Start Date
May 1 2005
Last Update
January 15 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SAD Clinical Services, BWH Psychiatry; 221 Longwood Ave.
Boston, Massachusetts, United States, 02115